Craig Bijou: Okay, thanks, Jan. And then maybe in a follow-up to Rich’s question on SurgiMend and the PMA there, and I appreciate you’re not changing timelines, and it’s still important to you guys, but I mean, is it fair to assume that that’s pushed out, that timeline needs to be pushed out, that you’d have to remediate the issues at Boston before you’ll kind of move forward with that process?
Lea Knight: Yes, I’ll take that. As I mentioned, we are still doing the evaluation coming out of the report that we got on Boston to understand if or how the SurgiMend PMA timeline will be implicated. And so, that work is still ongoing. So, again, when we know more, we’ll share more, but that’s where we stand right now.
Operator: Thank you. And one moment for our next question, and that will come from the line of Jayson Bedford with Raymond James. Your line is open.
Jayson Bedford: Good morning. So, you’ve kind of stressed the commitment to getting SurgiMend and PriMatrix back on the market. Have you started looking at manufacturing these products at another facility?
Jan De Witte: Look, Jayson, we are in our planning not excluding any option. And so, that’s where I want leave it at this point.
Jayson Bedford: How long would it take to get up and running at a new facility or another facility?
Jan De Witte: Again, we’re looking at what our options are and we’re committed to bring these products back to the market. There’s a great market opportunity for us. So, if there’s options, we will take them into account.
Lea Knight: I think the only thing I would add to that is, I think as we’ve talked about in the past, we have been building out capacity at another site in Boston called Braintree. And so, to Jan’s point, as we evaluate options, we’re looking at options across the board from Braintree and Boston perspective.
Operator: Thank you. And we do have time for one final question, and that will come from the line of Drew Ranieri with Morgan Stanley. Your line is open.
Drew Ranieri: Thanks for taking the question. Just on Acclarent, it looks like your guidance is kind of implying the same revenue base for 2022 for 2024. And I can understand some of those, there could be integration challenges. So, maybe just talk about what investments you are making in Acclarent today and what you have to make to get that business up to being a high single-digit grower over the next year or two. And second, just remind us on your deleveraging plans with leverage ticking up here post-deal. Thanks.
Lea Knight: Yes. So, thank you for the question. From Acclarent perspective, as I mentioned, we absolutely believe that business can be growth-accretive to our base. As it relates to 2024, we’re continuing to invest behind the sales force, again, to tap into that commercial leverage, as well as the R&D portfolio. Some of the new offerings we believe represent the greatest opportunity for us to deliver some of that high single-digit growth, so offerings in their TruDi nav system area. We have an expanded indication for eustachian tubes that will also help facilitate driving differentiated growth. And so, those are the areas we’re going to continue to build out during the course of this year as we’re doing the integration that will set up – position us well in 2025 to get to that point.
I think the other question was with respect to leverage and how we – what our outlook is there. So, following the close of Acclarent, and with all the upfront integration costs, we expect by the end of Q2 that our leverage will be slightly above our typical range of 2.5x to 3.5x. So, it’ll be slightly above the 3.5x range, but over the course of the back half of the year, as we again start realizing cash flows from Acclarent and other parts of our business continue to come online, we’ll be able to drive that back down below the 3.5x. So, we’ll be within our normal range of 2.5x to 3.5 by year-end.
Operator: Thank you. This concludes today’s program. Thank you all for participating. You may now disconnect and have a wonderful day.
